

Animal and Plant Health Inspection Service

CVB Regulatory Perspective -Toxoid Vaccines











Angela Walker, D.V.M., Ph.D. Center for Veterinary Biologics PEL Laboratory

Email: Angela.M.Walker@usda.gov









Center for Veterinary Biologics





Virus-Serum-Toxin Act



- Title 9 of the Code of Federal Regulation (9 CFR)
 - Section 113.5: General Testing-Product released only after testing to establish pure, safe, potent and efficacious veterinary biologic
- Veterinary Services Memorandum
- Center for Veterinary Biologics Notices
- Other Guidance Documents: Supplemental Assay Methods, Testing Protocols, Reagent Data Sheets

https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-biologics

- Product Specific: Outline of Production
 - Section V (Final Product Testing Requirements)



Toxoid Vaccines





Toxoid Vaccines

		Fraction	Level of Test		
L ₀	L ₊	C perfringens Type C	10 AU/mL		
Greatest amount of toxin	Least amount of toxin	C perfringens Type D	1 AU/mL		
that, when mixed with 1 AU,	that, when mixed with 1	C. sordellii	1 AU/mL		
		C. novyi	0.1 AU/mL		
		C. septicum	1 AU/mL		
Standard Antitoxin L ₀ Toxin	Standard Antitoxin L ₊ Toxin	Rabbit Antiserum	Toxin		



Toxoid Vaccines

Difference	US	EU		
Requirement for batch release	See Tal	ble		
Rabbits vaccinated	8+	10+		
Rabbit dose	≤ ½ Label Dose	≤ Label Dose		
Mouse Inoculation Route	IV	IV or IP		
Determination of units in rabbit antiserum	Lo toxin mixed w/ pooled rabbit antiserum	LD ₅₀ determination through titrations over time		
Mice per treatment group	5	2		

Release Requirement

Fraction	US	EU		
C perfringens Type C	10 AU/mL	10 IU/ml		
C perfringens Type D	2 AU/mL	5 IU/mL		
<i>C. novyi</i> Type B	0.5 AU/mL	3.5 IU/mL		
C. septicum	varies	2.5 IU/ml		



Cell Based Toxin-Antitoxin Assays

- Potency Test for Clostridium septicum Alpha Antitoxin Using a Cell Assay
 - VERO Cells
 - https://www.aphis.usda.gov/animal_health/vet_biologics/publications/ BBPRO1009.pdf
- Potency Test for Clostridium perfringens Type D epsilon Antitoxin Using a Cell Assay
 - MDCK Cells
 - https://www.aphis.usda.gov/animal_health/vet_biologics/publications/ BBPRO1008.pdf
- Both add increasing amounts of toxin to a standard and unknown antitoxin to determine the amount of antitoxin present by monitoring cell death



Cell Based Assays: Template

	1	2	3	4	5	6	7	8	9	10	11	12
Α		Standard Antitoxin						Unknown Serum				
B							ll I					
С		600	550	500	450	400	ive ce ontro	550	500	450	400	
D		1: (1:	1:	1:,		Li C	1:			1:	
Ε		in (in @	in @	in (in a	I	in (a	in @	in a	in a	
F		Tox	Tox	Tox	Tox	Tox	roxin ontro	Tox	Tox	Tox	Tox	
G							C · J					
Η												



Example 1

- ➢ Satisfactory Serial:
 Cell protection for unknown serum ≥ Cell protection of Standard
 - Purple wells are "Live" or "Protected"
- Example Results:
 - Standard protects cells at 1:500 toxin dilution
 - Unknown protects cells ≤ 1:400 toxin dilution
 - Disposition: Satisfactory





Example 2

- Satisfactory Serial:
 Cell protection for unknown serum ≥ Cell protection of Standard
 - Purple wells are "Live" or "Protected"
- Example Results:
 - Standard protects cells at 1:500 toxin dilution
 - Unknown protects cells > 1:550 toxin dilution
 - Disposition: Unsatisfactory



←Standard→ Control→

←Unknown→



Conversion of Release Testing

- Manufacturers that wish to switch to the cell assay method will be required to do a limited product validation
- CVB provide reagents to assist with validation
 - Working stocks (conserve reagents)
 - Note in your APHIS 2018 "Use for cell assay validation"
- The validation should include the CVB-furnished proficiency panel
 - IRP 639: Clostridium septicum Cell Assay Proficiency Panel
 - IRP 638: Clostridium perfringens Type D Cell Assay Proficiency Panel
- CVB welcomes feedback on the test methods

Importance of Animal Welfare

- CVB supports implementation of 3Rs in release testing.
- The goal of potency testing is to protect the animals in the field. All new assays must provide the same confidence as those currently approved in order to prevent their suffering.



C. septicum: Courtesy of the Department of Pathobiology, University of Guelph.



C. novyi: Courtesy of Dr. Henry Stämpfli..

https://www.merckvetmanual.com/ generalized-conditions/clostridialdiseases/malignant-edema



Conclusion

- Overview of the current regulatory approach
- Guidance documents for the cell assays that have undergone proof-of-concept testing at the CVB
- Reagents
 - Available domestically
- Contacts:
 - <u>Angela.M.Walker@usda.gov</u>
 - Janet.M.Wilson@usda.gov

